MSD’s Keytruda plus chemo backed by NICE for lung cancerMerck & Co/MSD’s Keytruda can be provided via the Cancer Drugs Fund for first-line treatment of non-small cell Share XMSD’s Keytruda plus chemo backed by NICE for lung cancerhttps://pharmaphorum.com/news/msds-keytruda-plus-chemo-backed-by-nice-for-lung-cancer/
Study resurrects Merck’s hopes for Keytruda in breast cancerJust a few weeks ago Merck & Co was lamenting a failed trial for Keytruda in triple-negative breast Share XStudy resurrects Merck’s hopes for Keytruda in breast cancerhttps://pharmaphorum.com/news/study-resurrects-mercks-hopes-for-keytruda-in-breast-cancer/
Merck claims a brace of head and neck cancer approvalsMerck & Co/MSD has done the double in head and neck cancer with a pair of FDA approvals Share XMerck claims a brace of head and neck cancer approvalshttps://pharmaphorum.com/news/merck-claims-a-brace-of-head-and-neck-cancer-approvals/
SMC approves medicines for breast cancer, skin cancer, schizophreniaThe Scottish Medicines Consortium (SMC) has given approvals to Lilly’s breast cancer drug Verzenios, Merck’s Keytruda and Allergan’s Share XSMC approves medicines for breast cancer, skin cancer, schizophreniahttps://pharmaphorum.com/news/smc-approves-medicines-for-breast-cancer-skin-cancer-schizophrenia/
Keytruda gets okay from FDA for adjuvant melanomaThe US FDA has approved Merck & Co’s Keytruda as an adjuvant treatment for patients with melanoma who Share XKeytruda gets okay from FDA for adjuvant melanomahttps://pharmaphorum.com/news/keytruda-gets-okay-from-fda-for-adjuvant-melanoma/
Keytruda combo set to become “standard of care” in kidney cancerAnalysts are predicting that a combination of Merck’s Keytruda and Pfizer’s Inlyta will become the standard of care Share XKeytruda combo set to become “standard of care” in kidney cancerhttps://pharmaphorum.com/news/keytruda-combo-set-to-become-standard-of-care-kidney-cancer/
Keytruda cuts risk of death by 31% in esophageal cancer trialMSD’s Keytruda has cut the risk of death by 31% in patients with esophageal or esophagogastric junction carcinoma Share XKeytruda cuts risk of death by 31% in esophageal cancer trialhttps://pharmaphorum.com/news/keytruda-cuts-risk-of-death-by-31-in-esophageal-cancer-trial/
Merck bags adjuvant okay for Keytruda in melanomaCheckpoint inhibitors have already revolutionised the treatment of advanced melanoma, and Merck & Co has just claimed approval Share XMerck bags adjuvant okay for Keytruda in melanomahttps://pharmaphorum.com/news/merck-bags-adjuvant-okay-for-keytruda-in-melanoma/
Merck & Co’s cancer blockbuster Keytruda funds cutting edge rare disease R&D in UKMerck & Co is enjoying blockbuster revenues as its cancer immunotherapy Keytruda is becoming standard of care in Share XMerck & Co’s cancer blockbuster Keytruda funds cutting edge rare disease R&D in UKhttps://pharmaphorum.com/r-d/views-analysis-r-d/merck-cancer-blockbuster-keytruda-funds-rare-disease/
